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     Proton beam therapy (PBT) is used for the treatment of skull
base tumors to precisely deliver high-doses of radiation to the
tumor volume while sparing normal brain tissue and other
organs at risk such as the optic apparatus, the brainstem and the
pituitary gland.  It offers superior dose distribution as compared
to photon radiation therapy. The clinical advantage of PBT over
photon techniques is the marked reduction in the integral dose to
the patient due to the absence of an exit dose beyond the proton
Bragg peak. Proton beam therapy has shown benefits in the
treatment of skull base tumors, uveal melanoma, optic pathway
gliomas, pituitary adenomas, acoustic neuromas, nasopharynx
and paranasal sinus tumors and spinal cord tumors.1-4. 
     A rare yet important complication following brain radiation
therapy is radiation necrosis5-7, i.e. the appearance of a new
ABSTRACT: Background: Discrimination between radiation necrosis and tumor progression after radiation therapy represents a
radiologic challenge. The aim of our investigation is to identify patterns of radiation necrosis on brain magnetic resonance imaging
(MRI) and positron emission tomography (PET) with Fluoroethyltyrosin (FET) after proton beam therapy (PBT) for skull base tumors.
Material and Methods: Five consecutive patients with extra-axial neoplasms were included, presenting a total of eight radiation necrosis
lesions (three clival chordomas; two petroclival chondrosarcomas; two women; mean age: 49 ± 18.2 years). Radiation necrosis was
defined as the appearance of abnormal enhancement on MRI after PBT decreasing over time, and additional histopathologic
confirmation in one patient. MRI and PET imaging were retrospectively analyzed by two experienced radiologists in consensus. Results:
All lesions were localized close to the primary tumor in the field of irradiation. Three patients showed bilateral symmetrical lesions. All
lesions showed T2 hyperintensity and T1 hypointensity. Cerebral blood volume (CBV) was reduced in all available studies. None of the
lesions showed a restricted diffusion. FET-PET (three patients) showed a higher uptake in four out of five lesions; three of which had a
mean tumor-to-background (TBRmean) uptake lower than 1.95 and FET uptake increasing over time and were correctly classified into
radiation necrosis. Conclusions: Most radiation necroses were in direct continuity with the primary tumor mimicking tumor progression.
The most consistent imaging findings for PBT radiation necrosis are low CBV without restricted diffusion and FET-PET TBRmean
lower than 1.95 or increasing uptake over time. Bilateral symmetric involvement may be another indicator of radiation necrosis.
RÉSUMÉ: Critères radiologiques de la nécrose après protonthérapie des tumeurs de la base du crâne. Contexte : La distinction entre la nécrose
due à l’irradiation et la progression de la tumeur après l’irradiation est un défi au point de vue radiologique. Le but de notre étude était d’identifier le
profil radiologique de la nécrose radio-induite à l’IRM et à la tomographie par émission de positons (PET) à la fluoroéthyltyrosine (FET) après le
traitement de tumeurs  de la base du crâne par protonthérapie (PT). Méthode : Cinq patients consécutifs, atteints de tumeurs extra-axiales et présentant
au total 8 lésions de nécroses radio-induites, ont été inclus dans l’étude (3 chordomes du clivus, 2 chondrosarcomes pétroclivaux). L’âge moyen des
patients était de 49 ± 18,2 ans et 2 étaient des femmes. La nécrose due à l’irradiation était définie par l’apparition d’un rehaussement anormal qui
diminuait avec le temps à l’IRM après la PT et par une confirmation histopathologique chez un patient. L’IRM et la PET ont été étudiées
rétrospectivement en consensus par deux radiologistes expérimentés. Résultats : Toutes les lésions étaient localisées dans le champ d’irradiation, près
de la tumeur primitive. Trois patients avaient des lésions bilatérales et symetriques. Toutes les lésions présentaient un hypersignal T2 et un hyposignal
T1.  Le volume sanguin cérébral (VSC) était diminué sur toutes les études disponibles. Aucune des lésions ne présentait une restriction de la diffusion.
Le FET-PET de 3 patients montrait une captation plus élevée de 4 lésions sur les 5 imagées. Trois de celles-ci présentaient un rapport moyen de la
captation tumorale sur celle du tissu avoisinant (TBRmean) plus faible que 1,95 avec une captation qui augmentait avec le temps; et ont été correctement
classifiées comme étant de la nécrose radio-induite. Conclusions : La plupart des lésions de nécrose due à l’irradiation étaient en continuité directe avec
la tumeur primitive mimant une progression de la tumeur. Les critères radiologiques les plus constants de la nécrose due à la PT sont un faible VSC sans
restriction de la diffusion et une captation moyenne au FET-PET (TBRmean<1.95) ou augmentant avec le temps. Une atteinte symétrique bilatérale peut
être un autre indicateur de nécrose due à l’irradiation.  
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ORIGINAL ARTICLE
lesion with irregular contrast enhancement, which may mimic a
true tumor progression. Radiation necrosis is often seen 3 to 12
months after radiation therapy6. Many studies have focused on
radiation necrosis following photon radiation therapy for intra
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and extra-axial tumors5,7,8. Its incidence after conventional
radiation therapy ranges from 5% to 24%9,10. The real incidence
of radiation necrosis is difficult to assess because of the
heterogeneity in the methodology of these studies. For example,
different treatment modalities are used and correlation to
histopathology is not available throughout. In addition most of
these studies were conducted before the widespread use of
modern neuroimaging tools11 and only a few of them assessed
radiation injury after PBT12. 
     Discrimination between radiation injury and true tumor
progression is of paramount importance for further medical care,
yet it represents a radiologic challenge. In the current
investigation, we aim to describe typical magnetic resonance
imaging (MRI) patterns of proton beam therapy induced intra-
axial brain necrosis based on a retrospective review of five
patients treated by surgery and proton therapy for clival
chordoma or petroclival chondrosarcoma. We report results of a
relatively new treatment (PBT) for which there is considerably
less empirical data compared to “standard” photon radiation
therapy. 
METHODS
Subjects 
     The local ethical committee approved this study. We
retrospectively reviewed MRI and positron emission
tomography (PET) examinations of five consecutive cases of
necrosis in extra-axial neoplasms between September 2010 and
June 2012. We included two patients with petroclival
chondrosarcoma (one male and one female) and three patients
with clival chordoma (two males and one female). The ages
ranged from 28 to 68 years (mean: 49 ± 18.2).
     These five patients were treated with PBT at the Paul Scherrer
Institut from June 2002 to January 2010, which treated during
this time period 73 skull base tumors (42 chordomas and 31
chondrosarcomas). Median administered dose was 74 GyE
(range, 68-74). High-energy protons were delivered with a
technique of 3 - 4 non-coplanar beams. 
     The inclusion criterium was appearance of abnormal intra-
axial enhancement on T1 gadolinium enhanced MRI after proton
beam therapy.
     The interval between the start of proton beam therapy and
appearance of abnormal enhancement ranged from 9.5 to 42
months (average 26.3 months +/- 14.3). The period of MRI
follow-up ranged from 30 to 120 months after proton therapy.
Necrosis was confirmed as a decrease in pathologic
enhancement in four out of five cases and by surgery followed
by histopathology of the surgical specimen in one patient (See
Table 1). Fluoroethyltyrosin-PET (FET-PET) was acquired after
intravenous administration of 300 MBq of 18F-FET, in one case
(patient 5) with a dynamic acquisition from 0 to 40 minutes after
injection and in two cases (patients 3 and 4) from 30 to 50
minutes after administration. FET-PET was performed 32, 43
and 77 months after the beginning of treatment for patients 3, 4
and 5, respectively. 
Radiological evaluation
     Two experienced radiologists retrospectively analyzed in
consensus the MRI and FET-PET studies. Since MRI imaging
was performed in the context of routine follow-up, MRI
protocols were not standardized. Imaging was performed on 1.5
and 3 Tesla routine MRI scanners. 
     The MRI evaluation criteria were location of the lesions,
presence of mass effect and perifocal edema (appearance and
signal intensity on T1, T2 and FLAIR sequences), signal
intensity on the T2 gradient echo sequence, relative cerebral
blood volume (CBV) on Dynamic Susceptibility Contrast (DSC)
perfusion imaging, the aspect of enhancement on the T1
gadolinium sequence, the presence of restricted diffusion on
Diffusion Weighted Imaging (DWI), and the Chol/NAA ratio on
spectroscopy.  
     The FET-PET evaluation was based on visible uptake (higher
than background), on quantitative measures of mean and
maximum tumor-to-background (TBRmean and TBRmax) ratio
and on the dynamic changes of uptake over time (30 to 40
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Radiation necrosis 
Confirmation 
1 
 
Petro-clival 
Chondrosarcoma 
28y 
2m M 70 9.5 30 
Spontaneous decrease of 
abnormal enhancement 
2 
 
Petro-clival 
Chondrosarcoma 
30y 
8m F 70 13 32 
Spontaneous decrease of 
abnormal enhancement 
3 
 
Sphenoidal and 
clival chordoma 
57y 
6m M 74 32 38 
Spontaneous decrease of 
abnormal enhancement 
4 
 Clival chordoma 
67y 
11m M 74 42 53 
Spontaneous decrease of 
abnormal enhancement 
5 
 
Clival chordoma 
 
60y 
6m 
 
F 
 
75 
 
35 
 
120 
 
Surgical resection of left 
temporal lesion 
 
 
               
 
 
able 1: Patient characteristics, radiation therapy information, follow-up period and confirmation of
radiation necrosis
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0317167100015924
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 19:32:50, subject to the Cambridge Core terms of use, available at
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
802
minutes interval, available for all subjects). The results of these
evaluation were expressed as three patterns: increasing over time
(Pattern I), stable (pattern II) or decreasing (pattern III), in
analogy to the classification recently proposed in an article
describing FET-PET features of radiation necrosis after photon
radiation therapy13.   
RESULTS
     Three patients had two lesions and two patients had one
lesion resulting in a total of eight lesions (Figures 1 - 5). Two out
of five patients had cardiovascular risk factors. One had
controlled high blood pressure and the other was an active
smoker (ten pack-year).
     One out of five patients was symptomatic, presenting a left
third nerve palsy with ptosis and diplopia. These symptoms
might have been related with the left temporal necrosis given the
spatial proximity between the radiation necrosis and the course
of the third cranial nerve. The remaining four patients were
asymptomatic. 
     The clinical course was uneventful for 4 out of the 5 patients
included with no clinical or radiological signs of relapse three
years (2 patients), four years (1 patient) and ten years and six
Figure 1: Patient 1. 28 yo. man with right petroclival chondrosarcoma (a) treated by partial resection followed by proton radiation therapy (70 Gray).
MRI follow-up 15 months after the beginning of radiation therapy (b) shows abnormal irregular enhancement (large arrows) in both tempo-medial
lobes, adjacent to the residual tumor and within the field of irradiation. Follow-up at 20 and 24 months (c, d) shows decrease and almost complete
disappearance of the abnormal enhancement (thin arrows), with a low CBV (circles on image c) confirming the diagnosis of radiation necrosis.
Figure 2: Patient 2. 30 yo. woman with right petroclival chondrosarcoma (a) treated by surgery and adjuvant proton radiation therapy. On the follow-
up MRI, 13 months after initiation of radiation therapy, presence of a new right cerebellar encephalocele through the surgical site with parenchymal
edema and heterogeneous enhancement (large arrow, image b). MRI follow-up at 20, 26 and 32 months (c,d,e) shows the resolution of the abnormal
enhancement (thin arrows) confirming radiation necrosis 
Figure 3: Patient 3. 57 years-old. man with clival chordoma (a) treated by partial resection and adjuvant proton radiation therapy (74 Gray). On the
follow-up MRI, 32 months after the proton therapy, visualization of bilateral abnormal irregular rim enhancement in both temporo-medial lobes (large
arrows), showing a significant uptake on FET-PET on the left (large arrow, image c). The lesions are located in both sides of the extra-axial medial
primary tumor and within the field of irradiation (b,c). The MRI at 34 and 38 months from radiation therapy shows a spontaneous decrease of the
abnormal enhancement (thin arrows, image d and e). The lesions shows low CBV on perfusion MR imaging (circle on image d) 
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months (1 patient) after the completion of proton therapy. One
patient with clival chordoma showed progression of his extra-
axial primary tumor four years after the completion of proton
therapy, nevertheless without extension to the brain parenchyma.
This tumoral progression was seen on the follow-up MRI.
Fluoroethyltyrosin-PET was not performed on this occasion for
this patient.  
Location
     In all cases, lesions were localized in close proximity to the
primary tumor in the area of irradiation. In three of the five
cases, lesions were located in an almost mirror symmetric
configuration. In four of the five cases, delineation of radiation
necrosis from the primary tumor was not clear, mimicking a
continuous lesion. 
     Although we did not perform a detailed dose-lesion analysis
(i.e. brain MRI and computed tomogram (CT) planning fusion),
all lesions were in the high-dose (> 90% prescribed dose) region.
Mass effect
     Four out of eight lesions presented mass effect. The
remaining four lesions were small (<1 cm) without mass effect. 
T2 sequence
     In all cases, we found hyperintensity with blurry margins,
larger than the heterogeneously enhanced area. The signal was
homogeneous in one lesion and heterogeneous in the remaining
seven lesions found in four patients. 
FLAIR sequence
     All lesions appeared hyperintense on FLAIR imaging. 
T2 gradient echo weighted sequence (T2*)
     In two patients, three lesions showed a focal and slight
gradient echo T2 hypointensity within the T2 hyperintensity. No
abnormality on the gradient echo T2 weighted images (T2*) was
seen in the remaining five lesions (3 patients). 
T1 sequence
     All eight lesions were hypointense on T1W imaging. 
Diffusion weighted imaging (DWI)
     In one patient, mild hyperintensity on the DWI b1000 was
noted in the left temporo-mesial lesion with heterogeneous low
signal on the apparent diffusion coefficient (ADC) cartography.
In addition, a T2* hypointensity was noted in the same area
Figure 4: Patient 4. 68 year-old. man with clival chordoma (a) treated by surgery and followed by proton radiation therapy (74 Gray). MRI done
45 months after the beginning of radiation therapy shows new bilateral abnormal enhancements of the medio-temporal lobes (large arrows, image
b); irregular and rim-like on the right, and less pronounced with a nodular, irregular and heterogeneous aspect on the left; the MR perfusion shows
no hypervascularisation and a low CBV of the lesions (circles on image b). Both lesions show a moderate uptake on FET-PET (large arrows on image
c). Follow-up MRI done at 49 and 55 months shows a decrease of the abnormal enhancement on both sides (thin arrows on images d and e),
confirming the diagnosis of radiation necrosis.
Figure 5: Patient 5. 60 year-old. woman with clival chordoma extending to the prebulbar space (a) treated by subtotal resection followed by proton
radiation therapy (75 Gray). 36 months after the beginning of radiation therapy, MRI follow-up shows new heterogeneous and irregular rim-like
enhancement in the left medio-temporal lobe surrounded by edema (large arrow, image b). The MRI at 46 and 85 months (c,d) shows the development
of a temporo-polar gliosis and decrease of the abnormal enhancement (thin arrows). The latter has a significant uptake on the FET-PET (thin arrow
on image d). The patient subsequently underwent resection of this heterogeneous lesion and the diagnosis of radiation necrosis was confirmed by
histopathology. The post-operative MRI, 106 months after radiation therapy (e), shows absence of abnormal enhancement.
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corresponding to blood. The abnormal signal on DWI might
therefore be related to hemosiderin and not to restricted
diffusion. No restricted diffusion was noted in the remaining
seven lesions.  
Gadolinium enhanced T1 sequence
     In four lesions of three patients, irregular rim enhancement
was observed. In four lesions of three patients, nodular and
heterogeneous enhancement with irregular margins was seen.
One patient with lesions in both temporal lobes showed irregular
rim enhancement on one side and nodular irregular enhancement
on the other side. 
Dynamic susceptibility contrast perfusion sequence
     In seven lesions of four patients, dynamic susceptibility
contrast MRI perfusion showed no hypervascularisation and a
decrease in the CBV. Perfusion analysis was not performed on
one patient with a unique lesion.
MR Spectroscopy
     Spectroscopy was available for three patients. For one patient
(patient number 2), the lesion was too small and too close to the
skull base for reliable spectroscopy to be performed.
     In two patients (patients number 3 and 4), reliable peaks were
obtained for NAA and Choline, but not for creatine. Hence we
only report the Chol/NAA ratios, which were 1.39 for patient 3
and 1.26 for patient 4. 
FET-PET imaging
     Fluoroethyltyrosin-PET hybrid imaging was performed for
three patients (patients 3 to 5) and showed a visible uptake higher
than background in four out of five lesions. For two lesions, the
TBRmean and TBRmax values were raised and higher than the
cutoff recently suggested for differentiating recurrent brain
metastases from radiation necrosis (>1.95 and >2.55,
respectively)13. Two lesions had an uptake increasing over time
(Pattern I), suggestive of radiation necrosis, whereas two lesions
had an uptake stable or decreasing (pattern II and III), previously
observed for brain metastasis13. However, when using the
combination of both TBRmean < 1.95 or pattern I as typical for
radiation necrosis three of the four lesions showing a visible
uptake had FET-PET features previously described in radiation
necrosis13. Results are summarized in Table 2.  
DISCUSSION
     In four out of five cases, the radiation necrosis appeared in
direct continuity with the primary tumor suggesting tumor
progression, which led to biopsy in one case. The intra-axial
location became evident only during follow-up imaging, which
highlights the importance of being familiar with the imaging
characteristics of PBT induced necrosis. The most consistent
imaging findings of PBT induced necrosis were hypoperfusion
with a low CBV without restricted diffusion. Bilateral symmetric
involvement, if present, may be another indicator of PBT
induced necrosis. 
     No lesion presented a restricted diffusion. This finding is in
agreement with the study of Kang and colleagues concerning
brain metastases treated with radiosurgery, which showed that
restricted diffusion with a low ADC value is more likely to be a
recurrent tumor. In fact, the latter demonstrates a higher
cellularity and less extracellular space available for the protons
to move14,15. 
     Concerning CBV, our results showing hypoperfusion are
concordant with the study by Friso and colleagues in the context
of brain metastases after stereotactic radiosurgery. Subjective
visual assessment of relative CBV (rCBV) map and a
quantitative measurement of rCBV were done on 20 tumor
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Combined analysis 
of kinetic pattern 
and TBRmean  
Patient 1  
Lesion 1 YES NO YES NO NO YES YES ---- 
    
Patient 1 
Lesion 2 YES NO YES NO NO YES YES ---- 
    
Patient 2   
Lesion 1 YES YES YES NO NO YES YES ---- 
    
Patient 3  
Lesion 1 YES YES YES NO YES NO YES YES 
3.3 2.6 Pattern III Tumor-like 
Patient 3  
Lesion 2 YES NO YES NO YES NO YES NO 
- - - - 
Patient 4  
Lesion 1 YES YES YES NO YES NO YES YES 
2.8 2 Pattern I Necrosis-like 
Patient 4  
Lesion 2 YES NO YES NO NO YES YES YES 
1.6 1.2 Pattern II Necrosis-like 
Patient 5 
Lesion 1 
 
YES 
 
YES 
 
YES 
 
NO 
 
YES 
 
NO 
 
   -- 
 
YES 
 
1.6 1.2 Pattern I Necrosis-like 
                
 
Table 2: Morphological and functional imaging characteristics of proton beam therapy induced radiation necrosis lesions
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recurrences and 14 tumor necroses suggesting that a high rCBV
is associated with tumor recurrence16. Our results are also in
agreement with the study by Essig and colleagues with 18
patients with brain metastases, showing that a low CBV value is
suggestive of treatment response despite the increase in tumor
volume probably related to radiation induced modifications17. 
     In three out of five cases, lesions were mirror-symmetric. The
median-paramedian position of the primary tumors (chordoma
and chondrosarcoma) treated by external PBT could be an
explanation for the symmetry of the necrosis lesions in both
temporal lobes, on both sides of the extra-axial tumor, and within
the field of high dose irradiation. By and large, we can assume
that the appearance of enhancing lesions on both sides of the
proton irradiation target, within the high dose field, is suggestive
of radiation necrosis. 
     In our study, all lesions showed hypersignal on T2W and
FLAIR imaging with corresponding hyposignal on T1WI
corresponding to perifocal edema. This suggests that these
sequences may not be useful for the diagnosis of radio-necrosis.
We acknowledge however that this assertion could only be made
with a matched cohort of patients with tumor progression. 
     In our sample, three patients with PBT induced necrosis had
FET-PET studies demonstrating a visible uptake in four out of
five lesions. The FET-PET positivity despite low CBV values
reflects the complex mechanism of tracer uptake, which is
influenced by perfusion, blood pool and blood-brain barrier
disruption, but also depends on specific amino-acidic
transporters in living cells, a measure of cellularity that CBV
cannot provide. A positive association between CBV and PET
signal has often been reported, but with relevant discrepancies
related to the specific processes reflected by the two markers18.
     The presence of a FET-PET uptake higher than background
tissue represents a diagnostic challenge. This has also been
described in recent reports19,20 while previous studies indicate
that FET-PET can be a valuable tool to detect recurrent
tumors21,22,13. A recent paper evaluated the performance of FET-
PET in differentiating recurrent brain metastases from radiation
necrosis, providing a cut-off value for uptake, relative to
background (TBRmean and TBRmax) and describing patterns of
uptake change over time more suggestive of tumor recurrence or
radiation necrosis13. Even with the assumption that the
recurrence of a skull base chordoma or chondrosarcoma would
have a different uptake value and possibly a different dynamic
behavior when compared to brain metastases, we tested the
robustness of the cutoff proposed in order to verify if the features
identified by the authors as “necrosis-like”, i.e. a moderately
increased uptake as compared with background (lower than
1.95) or an uptake increasing over time, might be an adjunct to
image interpretation in these doubtful cases. Importantly, we
observed FET-PET features suggestive of radiation necrosis in
three out of four lesions with a significant uptake, showing that
in the majority of cases, when uptake is visible, quantitative
evaluation of this uptake as compared with background and the
evaluation of uptake evolution over time can help to correctly
classify these patients. 
     Unfortunately, we could not find FET-PET studies in patients
with recurrent skull base chordomas or chordosarcomas in our
database or in the current literature. These data would be
required to validate the use of quantitative FET-PET measures
for the differential diagnosis of recurrent chordoma/
chordosarcoma versus radiation necrosis. Given the lack of
larger series of patients treated with proton therapy and the
absence of FET-PET data in these tumors, FET-PET for this
specific indication can only be used in support and association
with MRI evaluation and follow-up is ultimately always
required. A recent review compared the performance of the
various imaging modalities for the differential diagnosis of
recurrent glioma vs. radiation necrosis, suggesting that the most
sensitive and specific imaging modality was 201-Thallium
Single-Photon Emission Computed Tomography (SPECT) with
a sensitivity of 87.6% and specificity of 97.8%23. Surprisingly,
the results of FET-PET studies, yielding a sensitivity and
specificity of 92% in a series of 45 patients24, were not included
in the review. No comparative data are yet available concerning
the performance of the various imaging modalities for the
differential diagnosis of recurrent chordomas or
chondrosarcomas versus radiation necrosis.
     Proton MR spectroscopy (PMRS) appears to be a valuable
tool for differentiating recurrent tumor from radiation
necrosis25,26. The study by Weybright and colleagues26 using 2D
Chemical shift magnetic resonance (MR) spectroscopy on 16
patients with active tumors and 12 patients with radiation
injuries, showed that the Chol/Cr and Chol/NAA ratios were
significantly higher, and the NAA/Cr ratio was significantly
lower in tumor than in radiation injury.  In the latter study, mean
values for Chol/Cr, Chol/NAA and NAA/Cr ratios were
respectively 2.52, 3.48 and 0.79 for active tumor and 1.57, 1.31
and 1.22 for radiation injury. The primary tumors were intra-
axial lesions (glioma, primitive neuroectodermal tumor,
medulloblastoma, ependymoma, melanoma and acute
promyelocytic leukemia) treated by conventional non-protonic
radiation therapy26. Since all radiation necrosis lesions in our
study were in proximity to the bone, spectroscopy was difficult
to perform and Chol/NAA ratio for patients in our sample was in
the range of 1.3, which is concordant with the study by
Weybright and colleagues.  
Limitations 
     The major limitations of the current study are the small
sample size and its retrospective nature, which are due to the
relative rarity of radiation necrosis following a therapy which is
also infrequent. In addition, follow-up MRI was performed in a
clinical setting and therefore MRI protocols were not
standardized. Another limitation is that FET-PET had not been
performed in two patients and MR perfusion had not been done
in one patient. Magnetic resonance spectroscopy was performed
in only three out of the five patients. 
CONCLUSION
     Our results indicate that hypoperfusion and the absence of
restricted diffusion are typically found in radiation necrosis after
proton beam therapy for extra-axial neoplasms. If present,
bilateral lesions in the region of the irradiation field may be
another indicator of PBT induced necrosis. When available, a
moderate uptake increase seen in FET-PET or an uptake
increasing over time are suggestive of radiation necrosis. Our
MRI findings of radiation necrosis after proton beam therapy for
extra-axial lesions resemble previous reports of radiation injury
following conventional photon radiation therapy for intra-axial
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0317167100015924
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 19:32:50, subject to the Cambridge Core terms of use, available at
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
806
lesions. We therefore conclude that radiation necrosis after
proton beam therapy is a process at least partly independent from
the underlying pathology, indicating that our findings could be
generalized to other primary diseases.  
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